| Overview |
| bs-2809R-APC-Cy7 |
| HDAC4 Polyclonal Antibody, APC-Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Chicken, Rabbit |
| Specifications |
| APC-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human HDAC4 |
| 101-200/1084 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9759 |
| P56524 |
| Cytoplasm, Nucleus |
| HD4; AHO3; BDMR; HDACA; HA6116; HDAC-4; HDAC-A; Histone deacetylase 4; HDAC4; KIAA0288 |
| Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz